Sclerosis News and Research

RSS

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

AAN awards Cedars-Sinai researcher 2010 Sheila Essey Award for ALS research

The American Academy of Neurology (AAN) is awarding the 2010 Sheila Essey Award-An Award for ALS Research to Clive Svendsen, PhD, with the Cedars-Sinai Regenerative Medicine Institute in Los Angeles, CA. Svendsen will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

2010 John Dystel Prize for Multiple Sclerosis Research awarded to Yale University researcher

The American Academy of Neurology is awarding the 2010 John Dystel Prize for Multiple Sclerosis Research to David A. Hafler, MD, with Yale University. Hafler will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

WOCN Society launches campaign to raise awareness about benefits of specialized care

Patients and families who are dealing with conditions such as non-healing wounds, bedsores, bladder and bowel incontinence and ostomy-related issues contend with physical symptoms, as well as social and emotional side effects. The impact on patients and families can exact an enormous toll. The Wound Ostomy & Continence Nurses Society is launching a campaign to raise awareness about the benefits of specialized care.

31 Mar 2010

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Top neurologists to receive 2010 AAN Alliance Awards

The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.

31 Mar 2010

Study suggests two distinct versions of multiple sclerosis

There may be two distinct versions of multiple sclerosis, a study in both animal models and human blood samples suggests. What's more, a patient's responsiveness to the most popular first-line drug for this episodic and all-too-often recurring autoimmune condition seems to depend on which version that patient has.

30 Mar 2010

Conference on the actions of Vitamin D on human health

An important conference on the actions of Vitamin D on human health is being hosted by Barts and The London Medical School and the MRC Asthma UK Centre in Allergic Mechanisms of Asthma.

30 Mar 2010

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.

29 Mar 2010

UAB researchers discover first bio-marker for MS

Researchers at the University of Alabama at Birmingham have found the first bio-marker for multiple sclerosis that might predict which patients will respond to a standard therapy and which will not.

29 Mar 2010

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Medtronic, Inc. today announced the enrollment of the first European patients in the largest randomized controlled trial to date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in post-stroke patients affected by spasticity. The announcement comes as the World Congress for Neurorehabilitation is taking place in Vienna, Austria.

26 Mar 2010

Biogen Idec and Elan begin comparative trial of MS treatments

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.

25 Mar 2010

Payers can improve risk-sharing approaches for expensive therapies and technology

Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to the pharmaceutical and biotech fields, announced today that it has published the collective recommendations of an international team of healthcare experts on how payers can improve their risk-sharing approaches for expensive new therapies and technology.

25 Mar 2010

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.

25 Mar 2010

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

A Cedars-Sinai Heart Institute cardiologist has been awarded a three-year, nearly $1 million grant from the Muscular Dystrophy Association (MDA) to study whether drugs used to treat erectile dysfunction could also be used to improve muscle blood flow and reduce fatigue in muscular dystrophy patients.

25 Mar 2010

Patients to discuss future of health care system at Canadian Patient Summit

More than 100 patients living with chronic medical conditions will share their solutions for ensuring that patients are part of government decisions on the future of Canada's health care system.

24 Mar 2010

You and your baby may need vitamin D supplementation says research

This report appeared in the respected Journal Pediatrics this week. There has been growing awareness regarding deficiency of Vitamin D in children and adults. This vitamin is important for healthy bones, immunity and other bodily processes. In children inadequacy of this vitamin in diet may lead to bone damage, rickets, repeated infections and heart disease in later life.

23 Mar 2010

Ultraviolet portion of sunlight may play bigger role in controlling MS: Study

For more than 30 years, scientists have known that multiple sclerosis (MS) is much more common in higher latitudes than in the tropics. Because sunlight is more abundant near the equator, many researchers have wondered if the high levels of vitamin D engendered by sunlight could explain this unusual pattern of prevalence.

23 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010